DEA Forwards Psilocybin Rescheduling Petition to the HHS: What This Means for the Industry

In a significant procedural step, the DEA has forwarded Dr. Sunil Aggarwal's rescheduling petition - filed through the AIMS Institute - to the Department of Health and Human Services for scientific and medical evaluation. While this is far from a final decision, the move carries real weight for the emerging psilocybin industry.

What Happened

Dr. Aggarwal's petition requested that the DEA initiate proceedings to reschedule psilocybin from Schedule I to a lower classification. By forwarding the petition to HHS, the DEA has triggered a formal scientific review process - the same mechanism that President Biden invoked in October 2022 when he directed HHS and the Attorney General to review cannabis scheduling.

This is the process working as intended. HHS will now conduct its own evaluation of psilocybin's pharmacology, abuse potential, and accepted medical use. Their findings will be submitted back to the DEA, which will then decide whether to initiate rulemaking.

The 280E Connection

For psilocybin businesses currently operating in states with legal frameworks - Oregon chief among them - the scheduling question has enormous tax implications. Under IRC Section 280E, businesses that traffic in Schedule I or Schedule II controlled substances are denied standard business deductions.

If HHS acknowledges that psilocybin has accepted medical use - a finding that would support moving it out of Schedule I - there will be a substantial argument that 280E no longer applies to psilocybin businesses in the same way. The legal logic mirrors the arguments currently being advanced in the cannabis space, but with even stronger clinical evidence supporting medical utility.

Managing Expectations

It is important not to get ahead of ourselves. The HHS review process takes time. FDA approval for psilocybin-assisted therapy is still pending - multiple Phase III trials are underway, but none have completed the full regulatory pathway. Interstate commerce in psilocybin remains prohibited regardless of scheduling.

That said, this is a meaningful step. The fact that the DEA chose to forward the petition rather than reject it outright suggests that the agency recognizes the growing body of evidence supporting psilocybin's therapeutic potential.

This sets the stage for what could be an eventful 2026. Psilocybin operators should be working with advisors who understand the intersection of scheduling law, tax policy, and emerging regulatory frameworks - because the landscape is shifting faster than many realize.